Increased Development of Targeted Therapies in the Neuroendocrine Tumors Pipeline Promises a Shift in the Standard of Care

Figure 1: Active Phase II and Phase III Clinical Trials in Neuroendocrine Tumors in the 8MM by Therapeutic Class, 2020. Credit: GlobalData.